Back to mobile site
Get it on Google Play

AbbVie Skyrizi shows endoscopic gains in Crohn's disease trial

October 13, 2026 3:15 PM EDT Send to a Friend
AbbVie (NYSE: ABBV) presented new data from its Phase 3 AFFIRM study at the American College of Gastroenterology 2026 Annual ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login